secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K/A
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001140361-22-036093
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata provides financials of acquired Cend; CEND-1 in Phase 2b for pancreatic cancer
--------------------------------------------------------------------------------

- Merger of Cend into Lisata completed Sep 14, 2022; this amendment provides historical and pro forma financials of Cend.
- Cend's lead drug CEND-1 (iRGD peptide) in Phase 2b for 1L metastatic PDAC; Phase 1b showed promising safety and efficacy.
- Cend collaboration with Qilu Pharma for Greater China: $10M upfront, up to $225M in milestones, tiered royalties 10-15%.
- Cend recorded net income in 2021 from one-time license payment, but otherwise incurred losses since inception.
- Unaudited interim financials of Cend as of June 30, 2022 and pro forma combined financials of Lisata are filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/0001140361-22-036093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000114036122036093/brhc10042374_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-036093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer